Company Profile
PolyPid Stock Price, News & Analysis
- Ticker:
- PYPD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
4.81 USD (+4.57%)
Close
Last updated: August 6, 2026
93.4M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PYPD closed up 4.57% at $4.81. No new same-company headline was identified in the current news window.
Company overview
Local Controlled-Release Therapeutics
PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site.
PLEX Technology
The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks.
D-PLEX100
D-PLEX100 delivers doxycycline locally after colorectal surgery to prevent surgical-site infections while limiting systemic antibiotic exposure.
Future catalysts
PolyPid has initiated the modular NDA submission for D-PLEX100 and expects to complete the filing imminently.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PolyPid (PYPD)?
PolyPid (PYPD) most recently closed at 4.81 USD, a +4.57% move versus the previous session.
What is the market cap of PolyPid (PYPD)?
PolyPid currently has a market capitalization of 93.4M USD on BioPharmSignal.
What does PolyPid do?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks. D-PLEX100 D-PLEX100 delivers doxycycline locally after colorectal surgery to...
On which exchange is PYPD stock listed?
PolyPid (PYPD) is associated with NASDAQ, Israel, Biopharma.
What is Local?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site.
Which conditions is PolyPid targeting with Local?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks. D-PLEX100 D-PLEX100 delivers doxycycline locally after colorectal surgery to...
How does PolyPid describe recent progress with Local?
PolyPid has initiated the modular NDA submission for D-PLEX100 and expects to complete the filing imminently.
What is Controlled-Release?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site.